Virtual Library

Start Your Search

B.K. Chong



Author of

  • +

    P1.05 - Poster Session with Presenters Present (ID 457)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Early Stage NSCLC
    • Presentations: 1
    • +

      P1.05-038 - Patterns of Recurrence in Curatively Resected Stage I Lung Cancer (ID 6300)

      14:30 - 15:45  |  Author(s): B.K. Chong

      • Abstract
      • Slides

      Background:
      The patterns of recurrence after curative resection for pathologically stage I non-small cell lung cancer(NSCLC) were investigated according to the cell type.

      Methods:
      The medical records of stage I NSCLC patients who undergone curative resection at Asan Medical Center between 2000 and 2009 were reviewed.

      Results:
      Total 940 patients with pathologically proven stage I NSCLC were included. Patients with lepidic-type adenocarcinoma(LTA) were 74, other adenocarcinoma(ADC) 580, and squamous cell carcinoma(SCC) 246. Median length of follow-up was 62 months(3~189), median survival was 146 months, and median disease-free survival(DFS) was 109 months. During follow-up, recurrence occurred in 221 patients(23.5%). Number of recurrence is grouped by every 6 months. Incidence of recurrence was peaked within 2 years after resection, then gradually decreased thereafter. Recurrence LTA(AIS/MIA) group was significantly rare(13.5%) throughout the all follow-up period(median DFI of 60months), and its distribution shows relatively even distribution. Comparing ADC and SCC, ADC seemed to show better 5-year OS in univariate analysis(p=0.003), but not in multivariate analysis. Furthermore, there were no significant difference in 5-year DFS(p=0.331). ADC shows higher proportion of distant metastasis, even though ADC group has lower T-stage. SCC shows higher incidence of local recurrence. Figure 1



      Conclusion:
      Recurrence of ADC occured within 2 years after resection, and shows higher proportion of distant metastasis(74.0% Vs. 57.2) even though ADC group has lower T-stage. Most of recurrence of both ADC and SCC groups were peaked within 2 years after resection. LTA group shows significantly delayed pattern of recurrence.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P1.06 - Poster Session with Presenters Present (ID 458)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Advanced NSCLC
    • Presentations: 1
    • +

      P1.06-036 - Post-Recurrence Survival Analysis of Stage I Non-Small Cell Lung Cancer: Prognostic Significance of Local Treatment (ID 5805)

      14:30 - 15:45  |  Author(s): B.K. Chong

      • Abstract
      • Slides

      Background:
      The aim of this retrospective study was to review recurrence patterns of stage I non-small cell lung cancer(NSCLC), and to identify prognostic factors for post-recurrence survival(PRS).

      Methods:
      Among 940 patients with pathological stage I NSCLC who had undergone curative resection between 2001 and 2009, total 261 patients who had experienced recurrence were included in this study. Number of patients with adenocarcinoma(ADC) were 188, squamous cell carcinoma(SCC) were 62. Oligo-recurrence was defined as 1-3 loco-regional or distant recurrent lesions restricted to a single organ. Potentially-curative local treatment(PCLT) included surgery, stereotactic radiotherapy(SRT), and photodynamic therapy(PDT).

      Results:
      Median follow-up duration was 65 months(range, 4-186 months) and median disease-free interval(DFI) was 23 months(range, 2-95 months). Number of patients with oligo-recurrence was 154, and the most common sites of oligo-recurrence were lung in 84 patients, followed by brain in 18 patients, bronchial stump in 18, and single-station of mediastinal lymph nodes in 12. Local treatment for recurrent tumor included surgery in 59 patients, SRT in 50, PDT in 2, and other radiotherapy in 53. Seventy-four patients received chemotherapy only, and 36 patients took conservative treatment. Among 125 patients who were evaluated for EGFR gene mutation study, positive results was detected in 62 patients, and 31 patients were treated with TKI. The 3- and 5-year post-recurrence survival rates were 49.1% and 33.8%, respectively. Age at recurrence, adenocarcinoma cell-type, DFI, TKI and PCLT were independent prognostic factors in multivariate analysis. Figure 1



      Conclusion:
      Local treatment of oligo-recurrence should be considered in selected candidates, and use of TKI is reasonable if EGFR mutation is detected.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.